MedTrace Logo

Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.

NCT04069234 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2020-04-08

No results posted yet for this study

Summary

This study is designed to test the hypothesis that ticagrelor is superior to clopidogrel, in improving coronary microvascular function, as measured by coronary flow reserve (CFR) in patients with T2DM at high risk of cardiovascular (CV) events undergoing elective PCI.

Conditions

Interventions

DRUG

Ticagrelor

ticagrelor 60 mg BID for 30 days

DRUG

Clopidogrel

clopidogrel 75mg OD for 30 Days

Sponsors & Collaborators

  • IHF GmbH - Institut für Herzinfarktforschung

    collaborator OTHER

  • Hippocrates Research

    collaborator OTHER

  • IRW consulting AB

    collaborator UNKNOWN

  • AstraZeneca

    collaborator INDUSTRY

  • Region Skane

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-15
Primary Completion
2021-10-15
Completion
2022-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04069234 on ClinicalTrials.gov